Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7296578 | 1.00 | CASP1 (0.54) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL7298063 | 0.92 | CASP1 (0.63) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL7296624 | 0.86 | GNPAT (0.49) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL7285000 | 0.83 | CASP1 (0.64) | CASP1BACE1BACE2RENACE | |
| SCHEMBL7296792 | 0.83 | CASP1 (0.55) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL7296845 | 0.81 | GNPAT (0.47) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL5686946 | 0.81 | CASP1 (0.55) | CASP1CTSSCTSKBACE1BACE2 | |
| SCHEMBL9482934 | 0.79 | CASP1 (0.51) | CASP1BACE1BACE2 | |
| SCHEMBL7416737 | 0.79 | CASP1 (0.53) | CASP1BACE1BACE2RENACE | |
| SCHEMBL17732666 | 0.79 | BACE1 (0.51) | CASP1BACE1BACE2RENACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365612-B2 | Caspase inhibitors | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120294843-A1 | CASPASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-11-22 | — | — | US | disclosed |
| WO-2011094426-A1 | CASPASE INHIBITORS | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294843-A1 | CASPASE INHIBITORS | CASP1, CASP7, CASP14 | CASP1 1/4885CTSS 77/4885CTSK 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.